Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (44)

I-063Yixuan Cao

Physiologically-based pharmacokinetic model to predict loading dose polymyxin B exposure in critically ill patients with sepsis

Wed, Jun 3, 2026 10:30AM–12:00PM

I-064Antoine Croxo

MODEL-BASED TESTING TO ASSESS CMAX BIOEQUIVALENCE IN HIGHLY VARIABLE DRUGS

Wed, Jun 3, 2026 10:30AM–12:00PM

I-065Ricardo Diaz De Leon Ortega

USING PBPK MODELLING TO IDENTIFY PHYSIOLOGICAL CHANGES INDUCED BY CLF065, A GLP 2 RECEPTOR AGONIST, ON THE PHARMACOKINETICS OF ACYCLOVIR AND TO PREDICT POTENTIAL DRUG–DRUG INTERACTIONS WITH OTHER COMPOUNDS

Wed, Jun 3, 2026 10:30AM–12:00PM

I-066Meng Gu

A Whole-Body PBPK Model to Quantify Organ-Specific Biodistribution and Systemic Clearance of Bacteriophages

Wed, Jun 3, 2026 10:30AM–12:00PM

I-067Masoud Jamei

Assessing Cross-Version Simcyp Simulator Prediction Performance Using a Bioequivalence Framework to Support EMA Qualification

Wed, Jun 3, 2026 10:30AM–12:00PM

I-068Cong Liu

Integrating Endogenous Ligand Competition into a Mechanistic Whole-Body PBPK Model of Therapeutic Monoclonal Antibodies

Wed, Jun 3, 2026 10:30AM–12:00PM

I-069Neville Mwesigwa

Prediction of Hydroxyurea Pharmacokinetics and Dose Adjustment in Children with Mild, Moderate, and Severe Renal Impairment Using Physiologically Based Pharmacokinetic Modeling

Wed, Jun 3, 2026 10:00AM–12:00AM

I-070Pascale Rietveld

A physiologically-based pharmacokinetic model for intraperitoneal irinotecan to evaluate the impact of UGT1A1 variability on SN-38 exposure

Wed, Jun 3, 2026 10:30AM–12:00PM

I-071Oleg Stepanov

AI AUTOMATION MEETS PBPK: AN R SHINY APPLICATION WITH LARGE LANGUAGE MODEL INTEGRATION FOR EFFICIENT PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL REPORTING

Wed, Jun 3, 2026 10:30AM–12:00PM

I-072Paul Vrenken

Food effect prediction of high permeability/low solubility compound, formulated as an amorphous solid dispersion (ASD) using an Open Systems Pharmacology (OSP) PBBM approach

Wed, Jun 3, 2026 10:30AM–12:00PM

I-073Aole Zheng

AN OCULAR EXPOSURE PREDICTION FOR TOPICAL ATROPINE IN HUMANS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING

Wed, Jun 3, 2026 10:30AM–12:00PM

II-062Veronika Alberg

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF LOSARTAN FOR THE PREDICTION OF DRUG-DRUG- AND DRUG-GENE-INTERACTIONS

Wed, Jun 3, 2026 3:20PM–4:50PM

II-063Lisa Cheng

THE CRITICAL ROLE OF GASTRIC REACIDIFICATION IN PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELS INVESTIGATING FOOD EFFECT: A CASE STUDY WITH PICTILISIB

Wed, Jun 3, 2026 3:20PM–4:50PM

II-064Dorota Danielak

LEVERAGING SEMI-MECHANISTIC PHARMACOKINETIC MODELING TO ESTABLISH CLINICALLY RELEVANT DISSOLUTION SAFE SPACES IN COMPASS SOFTWARE

Wed, Jun 3, 2026 3:20PM–4:50PM

II-065Henry Enzama

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING FOR SUB-SAHARAN AFRICAN POPULATIONS: A REVIEW OF SYSTEM PARAMETERS AND VARIABILITY DRIVERS.

Wed, Jun 3, 2026 15:20PM–16:50PM

II-066Justine Henriot

PRECLINICAL PBPK MODELING FOR PERSONALIZED THERAPY AND DOTA-TATE-BASED RADIOPHARMACEUTICAL MODULARITY

Wed, Jun 3, 2026 3:20PM–4:50PM

II-067Helene Kenter

Accounting for Cell Settling Is Critical for Accurate In Vitro Trimer Formation Modeling of T Cell Engagers

Wed, Jun 3, 2026 3:20PM–4:50PM

II-068Panos Macheras

Finite Pharmacokinetics (FTPK) software: Strategic Acceleration of Oral Drug Development via Single-Point IV Pharmacokinetic Profiling

Wed, Jun 3, 2026 3:20PM–4:50PM

II-069Mariia Myshkina

PK-DB 2.0: An Open Pharmacokinetics and Pharmacodynamics Database for Pharmacometric Modeling, AI, and Digital Twins

Wed, Jun 3, 2026 3:20PM–4:50PM

II-070Marta Rodríguez Jiménez

A semi-mechanistic model for tumor regression effects of IL-2 receptor-targeted nanocarrires modulating Treg activity

Wed, Jun 3, 2026 3:20PM–4:50PM

II-071Nadia Toffoletto

DEVELOPMENT OF A GENERAL PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL OF DRUG DISTRIBUTION AFTER PERIOCULAR ADMINISTRATION

Wed, Jun 3, 2026 3:20PM–4:50PM

II-072Hyunju Yang

DEVELOPMENT OF NASAL PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL FOR NICLOSAMIDE TO QUANTIFY NASAL MUCOSA EXPOSURE

Wed, Jun 3, 2026 3:20PM–4:50PM

III-062Nikolaos Alimpertis

Finite Pharmacokinetics (FTPK) Software: A Giant Step Toward Model-Informed Drug and Generics Development (MIDGD)

Thu, Jun 4, 2026 9:50AM–11:20AM

III-063Hyojin Cho

Physiologically Based Pharmacokinetic Modeling to Evaluate Drug–Herbal Interactions Between Conventional GERD Therapies and Banhasasim-tang

Thu, Jun 4, 2026 9:50AM–11:20AM

III-064Wilbert de Witte

Validation and refinement of the large molecule biodistribution model in PK-Sim.

Thu, Jun 4, 2026 9:50AM–11:20AM

III-065Mgambi Gideon Gamba

UNDERSTANDING THE ORAL BIOAVAILABILITY OF VORICONAZOLE: A STEP TOWARDS A COMPREHENSIVE CYP2C19‑ AND CYP3A4‑MEDIATED DRUG‑DRUG‑GENE INTERACTION NETWORK

Thu, Jun 4, 2026 9:50AM–11:20AM

III-066Zhilan Huang

IMPACT OF CYP3A4 ONTOGENY ON PREDICTION OF DRUG CLEARANCE IN YOUNG PAEDIATRIC PATIENTS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING

Thu, Jun 4, 2026 9:50AM–11:20AM

III-067Jonas Langeraert

VALIDATION OF THE ACATPLUS MECHANISTIC COLONIC ABSORPTION MODEL IN GASTROPLUS USING A GUT-TARGETED COMPOUND

Thu, Jun 4, 2026 9:50AM–11:20AM

III-068Paulette Magnas

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF ELEXACAFTOR–TEZACAFTOR–IVACAFTOR DURING PREGNANCY WITH INTEGRATED EX VIVO HUMAN PLACENTAL TRANSFER DATA TO PREDICT MATERNAL AND FETAL EXPOSURE

Thu, Jun 4, 2026 9:50AM–11:20AM

III-069Adrien Olama

A FIT-FOR-PURPOSE PHYSIOLOGICALLY BASED PHARMACOKINETIC APPROACH FOR INTRANASAL ANALGESICS: APPLICATION TO KETAMINE AND FENTANYL ANALOGS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-070Priya Sharma

DISEASE-INFORMED PBPK MODELLING OF RIFAMPICIN: MECHANISTIC INTEGRATION OF BILE SALT–MEDIATED DISSOLUTION TO PREDICT PHARMACOKINETIC VARIABILITY IN HEPATOBILIARY CONDITIONS

Thu, Jun 4, 2026 09:50AM–11:20AM

III-071Severine Urdy

DEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGUATE WITH REZETECAN PAYLOAD IN MICE

Thu, Jun 4, 2026 9:50AM–11:20AM

III-072Shuying Yang

MODEL-INFORMED DRUG DEVELOPMENT FOR IBREXAFUNGERP IN ACUTE VULVOVAGINAL CANDIDIASIS: APPLICATION OF PBPK AND EXPOSURE–RESPONSE MODELING TO SUPPORT DRUG SUBSTANCE MANUFACTURING CHANGES

Thu, Jun 4, 2026 9:50AM–11:20AM

IV-062Liam V Brown

A simple algebraic expression can determine if a drug’s clearance is non-specific or target-mediated